UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 556

Sortiert nach

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

British journal of cancer, 2013-05, Vol.108 (10), p.2172-2177

2013

Link zum Volltext

Verfügbarkeit prüfen

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

Annals of oncology, 2011-07, Vol.22 (7), p.1561-1570

2011

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

Breast cancer research and treatment, 2013-07, Vol.140 (1), p.63-71

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

Journal of clinical oncology, 2005-01, Vol.23 (3), p.576-584

2005

Link zum Volltext

Verfügbarkeit prüfen

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy

Annals of surgical oncology, 2010-09, Vol.17 (9), p.2411-2418

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinical correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving adjuvant chemotherapy

Annals of oncology, 2012-09, Vol.23 (9), p.2301-2305

2012

Link zum Volltext

Verfügbarkeit prüfen

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy

European journal of nuclear medicine and molecular imaging, 2012-12, Vol.39 (12), p.1830-1838

2012

Link zum Volltext

Verfügbarkeit prüfen

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study

European journal of cancer (1990), 2003-09, Vol.39 (14), p.2006-2011

2003

Link zum Volltext

Verfügbarkeit prüfen

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

Annals of oncology, 2013-02, Vol.24 (2), p.537-542

2013

Link zum Volltext

Verfügbarkeit prüfen

Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients

Annals of oncology, 2002-09, Vol.13 (9), p.1387-1397

2002

Link zum Volltext

Verfügbarkeit prüfen

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy

Annals of oncology, 2011-04, Vol.22 (4), p.870-876

2011

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive characterization of matched pre-treatment biopsies and residual disease of chemotherapy treated breast cancer

European journal of cancer (1990), 2016-07, Vol.61, p.S30-S30

2016

Link zum Volltext

Verfügbarkeit prüfen

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

British journal of cancer, 2006-05, Vol.94 (9), p.1226-1230

2006

Link zum Volltext

Verfügbarkeit prüfen

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

British journal of cancer, 2003-02, Vol.88 (3), p.406-412

2003

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer

British journal of cancer, 2013-12, Vol.109 (12), p.2965-2972

2013

Link zum Volltext

Verfügbarkeit prüfen

PET/CT with 18 F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease

European journal of surgical oncology, 2017-04, Vol.43 (4), p.625-635

2017

Link zum Volltext

Verfügbarkeit prüfen

PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease

European journal of surgical oncology, 2017-04, Vol.43 (4), p.625-635

2017

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group

Journal of clinical oncology, , Vol.18 (14), p.2676-2684

Link zum Volltext

Verfügbarkeit prüfen

Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer

European journal of cancer (1990), 2009-09, Vol.45 (13), p.2284-2292

2009

Link zum Volltext

Verfügbarkeit prüfen

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy

Annals of oncology, 2010-03, Vol.21 (3), p.481-487

2010

Link zum Volltext

Verfügbarkeit prüfen

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure

Breast cancer research and treatment, 2015-08, Vol.153 (1), p.145-152

2015

Link zum Volltext

Verfügbarkeit prüfen

The Status of High‐Dose Chemotherapy in Breast Cancer

The oncologist (Dayton, Ohio), 2000-10, Vol.5 (5), p.369-375

Rodenhuis, S.

2000

Link zum Volltext

Verfügbarkeit prüfen

OC-0130 18F-FDG PET/CT FOR THE ASSESSMENT OF LOCOREGIONAL LYMPH NODE INVOLVEMENT IN STAGE II AND III BREAST CANCER

Radiotherapy and oncology, 2012-05, Vol.103, p.S51-S51

2012

Link zum Volltext

Verfügbarkeit prüfen

155. Locoregional lymph node involvement on 18F-FDG PET/CT and estimation of risk for locoregional recurrence in stage II–III breast cancer patients

European journal of surgical oncology, 2012-09, Vol.38 (9), p.783-783

2012

Link zum Volltext

Verfügbarkeit prüfen

7 Relevance of Breast Cancer Subtypes in Response Monitoring with 18F-FDG PET/CT During Neoadjuvant Chemotherapy

European journal of cancer (1990), 2012-03, Vol.48, p.S42-S42

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 556

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(508)
Mit Volltextzugriff
(507)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(319)
Humans
(305)
Life Sciences & Biomedicine
(279)
Female
(206)
Biological And Medical Sciences
(187)
Medical Sciences
(184)
Oncology
(179)
Middle Aged
(171)
Adult
(160)
Pharmacology. Drug Treatments
(111)
Aged
(106)
Male
(103)
Antineoplastic Agents
(75)
Breast Neoplasms - Drug Therapy
(75)
Chemotherapy
(75)
Tumors
(70)
Breast Cancer
(68)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(65)
Pharmacology & Pharmacy
(55)
Treatment Outcome
(48)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response

Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy

Clinical correlates of ‘BRCAness’ in triple-negative breast cancer of patients receiving adjuvant chemotherapy

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy

Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy

Comprehensive characterization of matched pre-treatment biopsies and residual disease of chemotherapy treated breast cancer

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

Neoadjuvant chemotherapy adaptation and serial MRI response monitoring in ER-positive HER2-negative breast cancer

PET/CT with 18 F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease

PET/CT with 18F-FDG predicts short-term outcome in stage II/III breast cancer patients upstaged to N2/3 nodal disease

Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure

The Status of High‐Dose Chemotherapy in Breast Cancer

OC-0130 18F-FDG PET/CT FOR THE ASSESSMENT OF LOCOREGIONAL LYMPH NODE INVOLVEMENT IN STAGE II AND III BREAST CANCER

155. Locoregional lymph node involvement on 18F-FDG PET/CT and estimation of risk for locoregional recurrence in stage II–III breast cancer patients

7 Relevance of Breast Cancer Subtypes in Response Monitoring with 18F-FDG PET/CT During Neoadjuvant Chemotherapy

Suchergebnisse filtern